A 35-year-old woman presents with severe cyclic mastalgia and breast nodularity consistent with fibrocystic breast disease. She has failed conservative measures (caffeine avoidance, supportive bra, NSAIDs). What is the drug of choice for pharmacological management of her mastalgia?

Explanation

## Pharmacological Management of Fibrocystic Breast Disease and Mastalgia ### Clinical Context Fibrocystic breast disease (FBD) is the most common benign breast condition in women of reproductive age. While most cases are self-limited and managed conservatively, severe cyclic mastalgia that fails first-line measures requires pharmacological intervention. ### First-Line Drug: Danazol **Key Point:** Danazol is the FDA-approved and most effective pharmacological agent for severe fibrocystic breast disease and cyclic mastalgia. It is the drug of choice when conservative measures fail. **High-Yield:** Danazol mechanism and efficacy: - **Class:** Androgenic progestin (synthetic steroid) - **Mechanism:** Suppresses FSH and LH, reduces estrogen and progesterone levels, and has direct androgenic effects on breast tissue - **Efficacy:** 70–90% response rate in severe mastalgia - **Dosing:** 100–200 mg daily (divided doses) for 3–6 months - **Onset:** 2–3 weeks; maximum benefit at 2–3 months ### Why Danazol is Superior | Drug | Efficacy | Side Effects | FDA Approval | Use in FBD | |------|----------|--------------|--------------|------------| | **Danazol** | 70–90% | Virilization, weight gain, liver dysfunction | Yes | **Gold standard** | | **Bromocriptine** | 50–60% | Nausea, dizziness, hypotension | Yes | Second-line (prolactin-related) | | **Tamoxifen** | 60–70% | Hot flushes, thromboembolism, endometrial cancer risk | No (off-label) | Reserved; significant toxicity | | **GnRH agonists** | 80–90% | Menopausal symptoms, bone loss | No (off-label) | Last resort; cost and toxicity | **Clinical Pearl:** Danazol is the only FDA-approved drug specifically for severe fibrocystic breast disease. It is the preferred first-line pharmacological agent when conservative measures (caffeine restriction, supportive bra, NSAIDs, evening primrose oil) fail. [cite:Sabiston Textbook of Surgery Ch 36] ### Monitoring and Contraindications **Warning:** Danazol carries significant androgenic side effects: - Virilization (clitoral enlargement, hirsutism, voice deepening) - Weight gain, acne, oily skin - Hepatotoxicity (rare but serious) - Lipid abnormalities - Contraindicated in pregnancy (teratogenic) **Tip:** Always use effective contraception with danazol. Baseline liver function tests and lipid panel are recommended. Monitor for signs of virilization and discontinue if they occur. ### Why Each Alternative Is Incorrect 1. **Tamoxifen** — While effective (60–70% response), it carries significant risks (thromboembolism, endometrial cancer) and is not FDA-approved for FBD. Reserved for cases where danazol is contraindicated. 2. **Letrozole** — An aromatase inhibitor used in postmenopausal breast cancer. No established role in premenopausal fibrocystic disease; not indicated. 3. **Spironolactone** — A potassium-sparing diuretic with some evidence in luteal-phase mastalgia (via aldosterone antagonism), but it is NOT the drug of choice and is less effective than danazol.